Correction: Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response (PLoS ONE (2003) 8, 2 (e56586) DOI:10.1371/journal.pone.0056586);Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Z Adzemovic, Milena ^a   Zeitelhofer, Manuel ^a   Eriksson, Ulf ^a   Olsson, Tomas ^a   Nilsson, Ingrid ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; DYSFERLIN; EOTAXIN; GAMMA INTERFERON; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 5; MESSENGER RNA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; EVENING DOSAGE; FEMALE; IMMUNE RESPONSE; MACROPHAGE; MORNING DOSAGE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UPREGULATION;

EID: 84874249820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/dd60f248-ca3f-4824-a3b4-c07aefb1c7c3     Document Type: Erratum

References (36)

1. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD, (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1: 223-236.
2. Ransohoff RM, Brown MA, (2012) Innate immunity in the central nervous system. J Clin Invest 122: 1164-1171.
3. Holman DW, Klein RS, Ransohoff RM, (2011) The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 1812: 220-230.
4. Ransohoff RM, Engelhardt B, (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12: 623-635.
5. Sospedra M, Martin R, (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
6. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, et al. (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8: 681-694.
7. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, et al. (2011) Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol 37: 24-39.
8. Fredriksson L, Li H, Fieber C, Li X, Eriksson U, (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J 23: 3793-3802.
9. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, et al. (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14: 731-737.
10. Ma Q, Huang B, Khatibi N, Rolland W, 2nd, Suzuki H, et al (2011) PDGFR-alpha inhibition preserves blood-brain barrier after intracerebral hemorrhage. Ann Neurol 70: 920-931.
11. Amor S, Groome N, Linington C, Morris MM, Dornmair K, et al. (1994) Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 153: 4349-4356.
12. Bradl M, Bauer J, Flugel A, Wekerle H, Lassmann H, (2005) Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cord. Am J Pathol 166: 1441-1450.
13. Bondjers C, He L, Takemoto M, Norlin J, Asker N, et al. (2006) Microarray analysis of blood microvessels from PDGF-B and PDGF-Rbeta mutant mice identifies novel markers for brain pericytes. FASEB J 20: 1703-1705.
14. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, et al. (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65: 855-865.
15. Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, et al. (1997) Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 110 (Pt 14): 1603-1613.
16. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD, (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192: 1075-1080.
17. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ, (2000) CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192: 899-905.
18. Sallusto F, Mackay CR, Lanzavecchia A, (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277: 2005-2007.
19. Adzemovic MZ, Ockinger J, Zeitelhofer M, Hochmeister S, Beyeen AD, et al. (2012) Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. PLoS One 7: e39794.
20. Zlokovic BV, (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
21. Zlokovic BV, (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738.
22. Thelen M, Stein JV, (2008) How chemokines invite leukocytes to dance. Nat Immunol 9: 953-959.
23. Ivanov, I.I, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133.
24. Goverman J, (2009) Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9: 393-407.
25. Mahad DJ, Ransohoff RM, (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15: 23-32.
26. Banisadr G, Queraud-Lesaux F, Boutterin MC, Pelaprat D, Zalc B, et al. (2002) Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81: 257-269.
27. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, et al. (2009) CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132: 2487-2500.
28. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, et al. (2007) CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179: 5228-5237.
29. Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, et al. (2011) Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol 31: 1010-1020.
30. Sato W, Aranami T, Yamamura T, (2007) Cutting edge: Human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J Immunol 178: 7525-7529.
31. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
32. Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, et al. (2012) Imatinib enhances functional outcome after spinal cord injury. PLoS One 7: e38760.
33. Olson LE, Soriano P, (2011) PDGFRbeta signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 20: 815-826.
34. Vermersch P, Benrabah R, Schmidt N, Zephir H, Clavelou P, et al. (2012) Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 12: 36.
35. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4: e7258.
36. Couturier N, Zappulla JP, Lauwers-Cances V, Uro-Coste E, Delisle MB, et al. (2008) Mast cell transcripts are increased within and outside multiple sclerosis lesions. J Neuroimmunol 195: 176-185.